Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2010 - 2026)

Celldex Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 52.93% year-over-year to $51.9 million in Q1 2026; TTM through Mar 2026 was $51.9 million, a 52.93% increase from a year earlier, with the FY2025 full-year figure at $51.8 million, up 23.68% from the prior year.
• Total Non-Current Liabilities steadied at $51.9 million in Q1 2026 per CLDX's latest filing, from $51.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $51.9 million in Q1 2026 and bottomed at $15.4 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $32.1 million (2023), against an average of $31.4 million.
• Across the five-year window, Total Non-Current Liabilities jumped 104.19% in 2022 and slumped 46.61% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $21.2 million in 2022, then soared by 51.21% to $32.1 million in 2023, then surged by 30.6% to $41.9 million in 2024, then increased by 23.68% to $51.8 million in 2025, then rose by 0.27% to $51.9 million in 2026.
• Per Business Quant, the three latest CLDX Total Non-Current Liabilities figures stand at $51.9 million (Q1 2026), $51.8 million (Q4 2025), and $47.5 million (Q3 2025).